Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices

Kolasa, Katarzyna; Kaló, Zoltán; Hornby, Edward

doi:10.1586/14737167.2014.898566

Cited by 9 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eastern Europe has also seen an increase in the number of published articles pertaining to their experiences with RSAs. Similar to the UK’s position on the adequate use of RSAs, a systematic literature review and expert analysis by Kolasa et al [ 59 ] determined that PBRSAs were better suited for real-world application when dealing with uncertainties surrounding cost effectiveness, and financial-based RSAs were deemed more appropriate for budgeting and cost containment. Since cost-effectiveness and budget-impact analyses have become a requirement in most healthcare systems for setting the reimbursement of highly innovative drugs, Zizalova et al [ 60 ] in the Czech Republic recently evaluated whether or not these costs matched those in the real world.…”

Section: Resultsmentioning

confidence: 99%

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

Piatkiewicz

Traulsen

Holm-Larsen

2017

PharmacoEconomics Open

View full text Add to dashboard Cite

ObjectiveOur objectives were to explore the changes in the level of interest in risk-sharing agreements (RSAs) in the EU during the last 15 years and the underlying reasons for these changes.MethodsA systematic literature review was conducted using PubMed, Scopus, Web of Science, and Embase. Articles identified were divided into ‘quantitative articles’ used to establish the level of interest and ‘qualitative articles’ used to identify the underlying trends in RSAs.ResultsThe literature search retrieved 2144 scientific articles. Data were extracted from 238 articles. Of these, 100 contained quantitative data and 138 contained qualitative data. The pace of articles being published about RSAs grew significantly in 2015, which related to the increase in interest in and knowledge about RSAs. The underlying reasons for the fluctuations were condensed into four overall themes: (1) push for value-based pricing, (2) economic crisis and further push to contain costs, (3) criticism of RSAs in the real world, and (4) diversification of RSAs to fit the purpose.ConclusionThe overall level of interest in RSAs in the EU has been increasing since 2000; therefore, articles reporting the number of RSAs implemented and case studies have been steadily growing as evidence is becoming more readily available. The number of qualitative articles reporting and discussing the underlying reasons for these changes in interest has largely fluctuated over the last 15 years. Despite these fluctuations, interest in RSAs remains high.Electronic supplementary materialThe online version of this article (doi:10.1007/s41669-017-0044-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

Piatkiewicz

Traulsen

Holm-Larsen

2017

PharmacoEconomics Open

View full text Add to dashboard Cite

show abstract

“…Alternatively, a financing mechanism that links reimbursement with drug performance can be introduced to validate cost-effectiveness claims. Following the preferences of expert payers, the second one should especially be taken into consideration in the CEE Region [ 32 ]. Temporary access to OMPs could be secured as long as an HTA agency envisages the opportunity for further real life data collection before a final recommendation has been completed.…”

Section: Discussionmentioning

confidence: 99%

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

Kolasa

Zwoliński

Zah³

et al. 2018

Orphanet J Rare Dis

Self Cite

View full text Add to dashboard Cite

BackgroundA Multi Criteria Decision Analysis (MCDA) technique was adopted to reveal the preferences of the Appraisal Body of the Polish HTA agency towards orphan drugs (OMPs).ResultsThere were 34 positive and 23 negative HTA recommendations out of 54 distinctive drug-indication pairs. The MCDA matrix consisted of 13 criteria, seven of which made the most impact on the HTA process. Appraisal of clinical evidence, cost of therapy, and safety considerations were the main contributors to the HTA guidance, whilst advancement of technology and manufacturing costs made the least impact.ConclusionsMCDA can be regarded as a valuable tool for revealing decision makers’ preferences in the healthcare sector. Given that only roughly half of all criteria included in the MCDA matrix were deemed to make an impact on the HTA process, there is certainly some room for improvement with respect to the adaptation of a new approach towards the value assessment of OMPs in Poland.Electronic supplementary materialThe online version of this article (10.1186/s13023-018-0803-9) contains supplementary material, which is available to authorized users.

show abstract

“…Studies on risk-sharing contracts have focused on defining their types and applicability [3–5, 13–17], on analyzing their characteristics and desirability from a theoretical perspective [6, 7, 12, 18–24], on summarizing real cases and their economic consequences [25–30] and on understanding the perceptions of the stakeholders involved in these contracts [31–34]. However, as Nazareth [34] remarked, despite the frequent use of risk-sharing agreements, little can be learned from them, as the information is not disclosed for confidentiality reasons.…”

Section: Introductionmentioning

confidence: 99%

Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists

2019

View full text Add to dashboard Cite

BackgroundConcerns about financial sustainability of health systems have promoted the adoption of risk-sharing agreements. Nevertheless, few insights have been derived, due to their confidentiality. The purpose of this study is to analyze to what extent these agreements have been implemented in Spain and the importance of several clinical and management variables concerning their use. We also explore whether risk-sharing agreements promote the adoption of personalized medicine. We give a descriptive analysis based on a questionnaire sent to members of the Spanish Society of Hospital Pharmacy, asking about the implementation of risk-sharing contracts in their hospitals.ResultsThere were 80 replies. Implementation of risk-sharing agreements was high (90%), being oncology, neurology, dermatology and infectious diseases the main specialties. The most relevant variables were the number of units of medication per year (89%) in price-volume agreements, and the efficacy and uncertainty of treatments (over 75%) in pay-for-performance agreements. Price-volume agreements were suitable for both conventional and personalized medicine and pay-for-performance more specific for personalized medicine. Paying for performance promotes genetic testing (85%).ConclusionsThe results suggest health authorities should encourage the assessment of financial and health outcomes of real-world contracts of conventional and personalized medicine to better know the variables influencing their use.

show abstract

Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices

Abstract: The results indicate that outcome-based schemes are better suited to deal with uncertainties surrounding cost effectiveness, while non-outcome-based schemes are more appropriate for pricing and budget impact challenges.

Cited by 9 publications

References 33 publications

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists

Contact Info

Product

Resources

About